Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 116
Selected: 0
NCT IDTitle
NCT06198296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
NCT00368082Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
NCT024397883RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA
NCT01333046Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
NCT01460901Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
NCT01192464EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
NCT00516087LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
NCT03690011Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
NCT00902044Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
NCT02291848Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
NCT05236764Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
NCT01447056Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
NCT02065362TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
NCT04219163Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
NCT03093350TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
NCT00703222A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells
NCT01853631Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
NCT01702961Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
NCT01494103Administration of Donor T Cells With the Caspase-9 Suicide Gene
NCT03192462TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
NCT01247701Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
NCT05103631Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
NCT00579137Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
NCT01070797Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
NCT04715191Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
NCT04345601Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
NCT01555892Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
NCT00062868LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
NCT05134740(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
NCT00058578Stem Cell Transplant to Treat Patients With Systemic Sclerosis
NCT04995003HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
NCT00058799Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
NCT03081910Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
NCT01109095CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
NCT00586274Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
NCT00069992Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
NCT00048412Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
NCT00590083Administration of Virus-Specific Cytotoxic T-Lymphocytes
NCT02287311Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
NCT00040482High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
NCT03774654CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
NCT01611298Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
NCT03768310CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
NCT00058786Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells
NCT00058604Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
NCT07197749Vitamin C With Steroids for Gastrointestinal GVHD
NCT06251544TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
NCT00224354Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
NCT01953900iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
NCT04377932Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors